The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Background Lenalidomide plus dexamethasone is a standard treatment for patients with
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell …

Background The combination of bortezomib, melphalan, and prednisone is a standard
treatment for patients with newly diagnosed multiple myeloma who are ineligible for …

Since the publication of the article entitled “Multiple Myeloma: EHA-ESMO Clinical Practice
Guidelines for Diagnosis, Treatment and Follow-up”(HemaSphere. 2021; 5: e528) …

Background High-dose chemotherapy plus autologous stem-cell transplantation has been
the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of …

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation
(ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or …

Background Lenalidomide plus dexamethasone is a reference treatment for patients with
newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with …

Multiple myeloma (MM) accounts for 1% of all cancers and $10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …